跳至主要内容
临床试验/NCT00211601
NCT00211601已完成不适用

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Merck Sharp & Dohme LLC0 个研究点目标入组 1,500 人开始时间: 2004年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,500
主要终点
CINV at the delayed phase during cycle 2

研究概览

简要总结

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

排除标准

  • Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis

结局指标

主要结局

CINV at the delayed phase during cycle 2

次要结局

  • Treatment for CINV

研究者

申办方类型
Industry
责任方
Sponsor

相似试验